Arcturus Therapeutics
ARCT
18 hedge funds and large institutions have $3.69M invested in Arcturus Therapeutics in 2018 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 5 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
3.07% less ownership
Funds ownership: 9.35% → 6.28% (-3.1%)
5% less funds holding
Funds holding: 19 → 18 (-1)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
53% less capital invested
Capital invested by funds: $7.87M → $3.69M (-$4.17M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$1.76M |
| 2 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$178K |
| 3 |
UCFA
United Capital Financial Advisors
Irving,
Texas
|
+$100K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$67.2K |
| 5 |
Morgan Stanley
New York
|
+$32.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$4.02M |
| 2 |
ARTA
A.R.T. Advisors
New York
|
-$128K |
| 3 |
JP Morgan Chase
New York
|
-$95K |
| 4 |
VF
Virtu Financial
New York
|
-$86K |
| 5 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
-$39.1K |
ARCT Hedge Fund Activity: Q1 2018 in Review
18 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Arcturus Therapeutics (ARCT) for Q1 2018, worth a combined $3.69M — down 53% from $7.87M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of ARCT and 4 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 5 added.
The largest buyer was ARK Investment Management, adding an estimated $1.76M. The largest seller was Franklin Resources, cutting an estimated $4.02M.
- 18 institutional investors held Arcturus Therapeutics (ARCT) as of Q1 2018, down from 19 in Q4 2017.
- Funds reported $3.69M of Arcturus Therapeutics stock for Q1 2018, down 53% quarter-over-quarter.
- 4 funds opened new Arcturus Therapeutics positions in Q1 2018 and 5 closed out, a net change of -1 holder.
- The largest Arcturus Therapeutics buyer in Q1 2018 was ARK Investment Management, an estimated $1.76M added.
- The largest Arcturus Therapeutics seller in Q1 2018 was Franklin Resources, an estimated $4.02M sold.
Based on aggregated 13F filings for Q1 2018.